Kouji; Hiroyuki

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kouji; Hiroyuki.The latest application filed is for "3,6-methano-1h-pyrrolo[3,2-b]pyridine and 3,6-methano-1h-pyrrolo[3,2-c]pyridine compounds and medicaments using same".

Company Profile

3.14.30

Kouji; Hiroyuki - Yokohama JP
Kouji; Hiroyuki - Yufu-shi JP
Kouji; Hiroyuki - Yufu JP
Kouji; Hiroyuki - Oita-shi Oita
Kouji; Hiroyuki - Kanagawa JP
Kouji; Hiroyuki - Yokohama-shi JP
Kouji; Hiroyuki - Yokohama-shi, Kanagawa JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor Grant 11,369,623 - Odagami , et al. June 28, 2	2022-06-28
3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME App 20220194942 - Kouji; Hiroyuki ; et al.	2022-06-23
3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same Grant 11,292,794 - Kouji , et al. April 5, 2	2022-04-05
Anti-erythropoietin Receptor Peptide App 20220041657 - Kouji; Hiroyuki ; et al.	2022-02-10
Compounds And Medicaments Using Same App 20210214356 - Kouji; Hiroyuki ; et al.	2021-07-15
Prevention or treatment agent for hepatic fibrosis Grant 10,265,331 - Odagami , et al.	2019-04-23
Alpha Helix Mimetics And Methods Relating Thereto App 20180305373 - Odagami; Takenao ; et al.	2018-10-25
Alpha helix mimetics and methods relating thereto Grant 10,017,522 - Odagami , et al. July 10, 2	2018-07-10
Anticancer Agent App 20180185395 - Odagami; Takenao ; et al.	2018-07-05
Prevention Or Treatment Agent For Hepatic Fibrosis App 20170266212 - ODAGAMI; Takenao ; et al.	2017-09-21
Prevention or treatment agent for hepatic fibrosis Grant 9,700,569 - Odagami , et al. July 11, 2	2017-07-11
Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Grant 9,682,996 - Kouji , et al. June 20, 2	2017-06-20
CRYSTAL (1) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND App 20160318957 - KUSHIDA; Ikuo ; et al.	2016-11-03
CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND App 20160318938 - KUSHIDA; Ikuo ; et al.	2016-11-03
Treatment Of Hepatic Fibrosis Using An Inhibitor Of Cbp/catenin App 20160263131 - KOUJI; Hiroyuki ; et al.	2016-09-15
Treatment Of Viral And Infectious Diseases Using An Inhibitor Of Cbp/catenin App 20160244453 - KOUJI; Hiroyuki ; et al.	2016-08-25
Method Of Producing Pyrazino[2,1-c][1,2,4]triazine Compound App 20160215007 - ISOMURA; Minetaka ; et al.	2016-07-28
Method For Treating Type I And Type Ii Diabetes App 20160166578 - KOUJI; Hiroyuki ; et al.	2016-06-16
Treatment Of Pulmonary Fibrosis Using An Inhibitor Of Cbp/catenin App 20160166577 - KOUJI; Hiroyuki ; et al.	2016-06-16
Alpha Helix Mimetic Compositions For Treating Cancer And Other Cbp/catenin-mediated Diseases And Conditions App 20150376204 - Kouji; Hiroyuki ; et al.	2015-12-31
Alpha Helix Mimetics And Methods Relating Thereto App 20150368262 - Odagami; Takenao ; et al.	2015-12-24
Alpha helix mimetics and methods relating thereto Grant 9,193,734 - Odagami , et al. November 24, 2	2015-11-24
Prevention Or Treatment Agent For Hepatic Fibrosis App 20150306115 - ODAGAMI; Takenao ; et al.	2015-10-29
Methods For Treating Eye Disorders App 20150284393 - Kouji; Hiroyuki ; et al.	2015-10-08
Treatment Of Hyperproliferative And Pre-cancerous Skin Diseases Using An Inhibitor Of Cbp/catenin App 20150283145 - Kouji; Hiroyuki ; et al.	2015-10-08
Treatment Of Scleroderma Using An Inhibitor Of Cbp/catenin App 20150274751 - Kouji; Hiroyuki ; et al.	2015-10-01
Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Grant 9,126,981 - Kouji , et al. September 8, 2	2015-09-08
Alpha helix mimetics and methods relating thereto Grant 9,040,531 - Odagami , et al. May 26, 2	2015-05-26
Method For Treating Type I And Type Ii Diabetes App 20140275295 - Kouji; Hiroyuki ; et al.	2014-09-18
Alpha Helix Mimetic Compositions For Treating Cancer And Other Cbp/catenin-mediated Diseases And Conditions App 20140221657 - Kouji; Hiroyuki ; et al.	2014-08-07
Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Grant 8,691,819 - Kouji , et al. April 8, 2	2014-04-08
Alpha Helix Mimetics And Methods Relating Thereto App 20140051706 - Kouji; Hiroyuki ; et al.	2014-02-20
Alpha Helix Mimetics And Methods Relating Thereto App 20130267482 - Odagami; Takenao ; et al.	2013-10-10
Alpha helix mimetics and methods relating thereto Grant 8,455,488 - Odagami , et al. June 4, 2	2013-06-04
Compound Capable Of Binding To Naturally Occurring Denatured Protein, And Method For Screening For The Compound App 20120296067 - Kouji; Hiroyuki	2012-11-22
Alpha Helix Mimetics And Methods Relating Thereto App 20120088770 - Odagami; Takenao ; et al.	2012-04-12
Alpha Helix Mimetics In The Treatment Of Cancer App 20110263607 - Kouji; Hiroyuki ; et al.	2011-10-27
Alpha Helix Mimetics And Methods Relating Thereto App 20110092459 - Odagami; Takenao ; et al.	2011-04-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.